NEW YORK, Jan. 13 (Xinhua) -- Johnson & Johnson (J&J), the American multinational pharmaceutical, biotechnology, and medical technologies corporation, agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about 15 billion U.S. dollars, evidence of the pharmaceutical industry's renewed interest in neuroscience bets with vast but unrealized promise, The Wall Street Journal reported Monday.
The deal would add to J&J's portfolio an Intra-Cellular drug branded Caplyta, a pill that treats bipolar depression and schizophrenia. Analysts predict the drug's sales could reach 4 billion dollars a year by 2030 if regulators approve expanding its use to include major depressive disorder.
